Home › Funds › Artal Group S.A. › LXRX

Artal Group S.A. position in LXRX

LEXICON PHARMACEUTICALS INC · Health Care

Artal Group S.A. reported holding 175,156,062 shares of LXRX (LEXICON PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$329.3M, representing 47.96% of its reported portfolio and ranking #2 among its reported holdings. Artal Group S.A. has disclosed LXRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)175.16M sh
Reported value held$329.29M
Portfolio Weight47.96%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Artal Group S.A.'s LXRX position evolved

Artal Group S.A. first disclosed a stake in LXRX in Q3 2023 at 117,553,284 shares (US$128.1M). The position peaked in Q2 2026 at 175,156,062 shares, worth US$420.4M. Across 13 filings, Artal Group S.A. increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 175,156,062 shares valued at US$329.3M. Notable position changes include a 49% increase in Q2 2024 (shares fell 7% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 117.55M $128.13M New
Q4 2023 117.55M $179.86M Hold
Q1 2024 117.55M $282.13M Hold
Q2 2024 175.10M $294.17M Add
Q3 2024 136.18M $213.80M Reduce
Q4 2024 136.18M $100.77M Hold
Q1 2025 136.18M $62.64M Hold
Q2 2025 136.18M $129.37M Hold
Q3 2025 136.18M $183.84M Hold
Q4 2025 136.18M $156.61M Hold
Q1 2026 154.73M $241.39M Add
Q2 2026 175.16M $420.37M Add
Q3 2026 175.16M $329.29M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LXRX and 13F data

LXRX (LEXICON PHARMACEUTICALS INC) is a Health Care company. 27 other funds we track also report a position in LXRX — the largest reported positions include Siren, L.L.C. (US$83.3M), Sessa Capital IM, L.P. (US$45.5M), Ishara Investments LP (US$3.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LXRX

All LXRX fund holders →

FAQ

How long has Artal Group S.A. held LXRX?

Artal Group S.A. has disclosed LXRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Artal Group S.A.'s current position in LXRX?

As of Q3 2026, Artal Group S.A. holds 175.16M shares of LXRX (LEXICON PHARMACEUTICALS INC), valued at $329.29M, representing 47.96% of its reported portfolio and ranking #2.

Has Artal Group S.A. been buying or selling LXRX?

In the latest 13F filing (Q3 2026), Artal Group S.A. held unchanged its position in LXRX. The position peaked in Q2 2026 at 175.16M shares.

Which other funds hold LXRX?

Other major institutional holders of LXRX include Siren, L.L.C., Sessa Capital IM, L.P., Ishara Investments LP, among 27 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.